ClinicalTrials.gg
Enrolling by invitationNCT06256887SONNOUpdated Feb 13, 2024

Sleep Spindles Organization as an Early Neural Marker of Neuromotor Outcome

An observational study in EEG Sleep Spindles, Motor Outcome and Cerebral Palsy, sponsored by IRCCS Fondazione Stella Maris. Enrolling by invitation at 3 sites in Italy. Open to participants aged 2 Months to 5 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-13.

Sponsored by IRCCS Fondazione Stella Maris · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
2 Months to 5 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Cerebral Palsy by IRCCS Fondazione Stella Maris — 10 open to participants now, 10 under way, none of them phase 3. Cerebral Palsy · IRCCS Fondazione Stella Maris.

Started
2023
with 2 others
Observational
8 of 16
6 open now
Registered
8th of 16
by date

Among the 16 studies in Cerebral Palsy by IRCCS Fondazione Stella Maris, this one is one of 3 that started in 2023, is one of 8 observational ones, and was the 8th registered.

Cerebral Palsy

1,942 studies on the registry are indexed under Cerebral Palsy; 456 are open to participants now.

Browse Cerebral Palsy studies →

Open to participants now

10 of the 16 studies in Cerebral Palsy by IRCCS Fondazione Stella Maris are open now, in 2 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 271 Cerebral Palsy studies recruiting now, 26 (10%) set no upper age limit and 237 (87%) stop at 75 or younger; 256 take children under 18; 53 take healthy volunteers.

This study: 2 Months to 5 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Cerebral Palsy by IRCCS Fondazione Stella Maris, or all of them as a file.
02

Study summary

The goal of this observational study is to test the effectiveness of quantitative early biomarkers in the sleep electroencephalogram (EEG), namely sleep spindles, as predictors of early sensorimotor maturation and long-term motor outcome. Spindles are discrete events, prominent over sensorimotor areas, that reflect motor learning overnight consolidation. They represent a potential marker for the investigation of altered early sensorimotor reorganization and long-term motor outcomes in the case of neuromotor pathologies. To test this hypothesis, we will validate the prognostic accuracy of a semi-automated EEG sleep-spindles analysis in two clinical populations: 1) infants with a perinatal brain lesion, at risk of Cerebral Palsy (CP), 2) infants with Spinal muscular atrophy type 1 (SMA1), a neuromuscular disease detectable at birth with variable response to early pharmacological treatment. A group of typically developing infants (at very low neurological risk) will be enrolled in the study as control group. All participants will undergo two sleep EEG recordings at 2-5 months (T1) and 12 months (T2), respectively. Short-term neuromotor outcome will be evaluated at T1 and T2, through standard and validated assessment. Long-term neuromotor development will be defined at 18 months (T3; i.e. CP vs NO CP; SMA treatment responders vs No responders). Primary clinical and motor outcomes will be used for estimating the effectiveness of spindles' features at T1 and T2 as predictors of later clinical and motor outcomes at T3. EEG sleep features will be considered both cross-sectionally, at each time point (T1, and T2), and from a longitudinal perspective. Differences in the EEG sleep-spindle features will be evaluated within- and between-groups.

03

Conditions studied

  • EEG Sleep Spindles
  • Motor Outcome
  • Cerebral Palsy
  • SMA1

Browse trials for

Keywords

  • Infant
  • Sensorimotor Development
  • Automatic spindle detector
  • Biomarker
  • EEG
04

Who can participate

Ages eligible
2 Months to 5 Months
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

  • Infants at risk of Cerebral Palsy
  • Infants with diagnosis of SMA type 1
  • Infants at very low neurodevelopmental risk (control group)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants aged 0-5 months who are at high-risk of Cerebral Palsy (CP): preterm and at term infants with a documented pre- or perinatal brain lesion at the neonatal brain MRI (i.e. hypoxic-ischemic brain injury, ischemic or hemorrhagic stroke, cystic periventricular leukomalacia, periventricular hemorrhagic infarction associated with germinal matrix-intraventricular haemorrhage);
  • Infant aged 0-5 months who have received the diagnosis of SMA1, according to the perinatal genetic screening, and undergo early pharmacological treatment;
  • Infants aged 0-5 months at very low neurodevelopmental risk (Control group): infants born preterm or at term in absence of perinatal neurological complications.

Exclusion criteria

Exclusion Criteria (apply all groups):

  • Presence of drug-resistant epilepsy or active epilepsy at T1,
  • Severe sensory deficits (blindness or deafness)
  • Diagnosis of progressive neurological disorders, other than SMA.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • Infants at risk of Cerebral Palsy

    N= 20, Infants at risk of Unilateral Cerebral Palsy (UCP); N= 20, Infants at risk of Bilateral Cerebral Palsy (BCP).

  • Infants with diagnosis of SMA1

    N=20, Infants with a diagnosis of SMA type 1.

  • Infants at very low neurodevelopmental risk (control group)

    N=20, Infants born preterm or at term in absence of perinatal neurological complications, therefore a very low neurodevelopmental risk.

06

What researchers measure

Primary outcomes

  1. Clinical dichotomous outcome

    For infants with perinatal brain damage, the primary outcome will be the diagnosis of CP: CP-YES vs CP-NO. For infants with SMA, the primary outcome will be the response to treatment: responders (SMA-R) vs non-responders (SMA-NR).

    Time frame: 18 (+/- 3) months

  2. Sleep EEG (T1,T2) - quantitative sleep spindles analysis

    Primary predictive measure of the study

    Time frame: 2-5 months, 12 (+/- 1) months

Secondary outcomes

  1. General Movements Assessment (GMA; T1)

    Short-term motor outcome

    Time frame: 2-5 months

  2. Peabody Developmental Motor Scale (PDMS-II; T2 and T3)

    Long-term motor outcome

    Time frame: 12 (+/- 1) months, 18 (+/- 3) months

  3. Hammersmith Infant Neurological Examination (HINE; T1, T2 and T3)

    Clinical short- and long-term outcome

    Time frame: 2-5 months, 12 (+/- 1) months, 18 (+/- 3) months

07

Study locations

3 sites
08

References and documents

Publications

  • Marchi V, Rizzi R, Nevalainen P, Melani F, Lori S, Antonelli C, Vanhatalo S, Guzzetta A. Asymmetry in sleep spindles and motor outcome in infants with unilateral brain injury. Dev Med Child Neurol. 2022 Nov;64(11):1375-1382. doi: 10.1111/dmcn.15244. Epub 2022 Apr 20. PubMed 35445398 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Feb 2026, 27 months after the start.

Of 217 non-industry observational studies under Cerebral Palsy, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 60. This study's planned 27 months is above that.

Counting every sponsor, half of 221 studies reached it within 21 months; a quarter within 8 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2024
First posted
Feb 13, 2024
StartActual
Nov 30, 2023
Primary completionEst.
Feb 2026
CompletionEst.
Apr 2026
Last update
Feb 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06256887
Lead sponsor
IRCCS Fondazione Stella Maris
Responsible party
Viviana Marchi (MD, PhD, IRCCS Fondazione Stella Maris) — Principal investigator
First posted
Feb 13, 2024
Start date
Nov 30, 2023
Primary completion
Feb 2026 (estimated)
Completion
Apr 2026 (estimated)
Last update
Feb 13, 2024

Study contacts

Viviana Marchi, MD, PhD
principal investigator · IRCCS Fondazione Stella Maris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion